Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.79
(
-1.85%
)
Bitcoin
74,054.91
(
0.15%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 57460

Tuesday, 01/15/2008 5:48:56 AM

Tuesday, January 15, 2008 5:48:56 AM

Post# of 257253
>BIIB announced earlier this month that avonex is still the #1 sold MS drug? is this still correct?<

Just barely. Avonex sold at a $1.82B annualized rate in 3Q07 while Copaxone sold at a $1.76B annualized rate. However, Avonex’s year-over-year growth was only 2% while Copaxone’s growth was 24%.

Copaxone will likely overtake Avonex in worldwide sales during 1Q08 if it hasn’t already done so in 4Q07.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now